Protagonist Therapeutics, Inc Operating Expenses
Protagonist Therapeutics, Inc (PTGX) reported Operating Expenses of $54.71 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Protagonist Therapeutics, Inc operating expenses for the quarter ending 2026-06-30 was $54.71M, a 14.97% increase year-over-year.
- Protagonist Therapeutics, Inc operating expenses for the quarter ending 2026-03-31 was $60.02M, a 26.00% increase year-over-year.
- Protagonist Therapeutics, Inc operating expenses for the quarter ending 2025-12-31 was $57.79M, a 31.77% increase year-over-year.
- Protagonist Therapeutics, Inc operating expenses for the quarter ending 2025-09-30 was $51.13M, a 10.85% increase year-over-year.
- Protagonist Therapeutics, Inc operating expenses for fiscal 2025 was $204.14M, a 12.42% increase from fiscal 2024.
- Protagonist Therapeutics, Inc operating expenses for fiscal 2024 was $181.59M, a 18.18% increase from fiscal 2023.
- Protagonist Therapeutics, Inc operating expenses for fiscal 2023 was $153.65M, a 2.72% decline from fiscal 2022.
- Protagonist Therapeutics, Inc operating expenses for fiscal 2022 was $157.95M, a 3.10% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $54.71M 10-Q · filed 2026-08-05 | $114.72M 10-Q · filed 2026-08-05 | $172.52M derived: sum of 3 quarters · filed 2026-08-05 | $223.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $60.02M 10-Q · filed 2026-05-05 | $117.81M derived: sum of 2 quarters · filed 2026-05-05 | $168.94M derived: sum of 3 quarters · filed 2026-05-05 | $216.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $57.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $108.92M derived: sum of 2 quarters · filed 2026-02-25 | $156.51M derived: sum of 3 quarters · filed 2026-08-05 | $204.14M 10-K · filed 2026-02-25 |
| 2025-09-30 | $51.13M 10-Q · filed 2025-11-06 | $98.72M derived: sum of 2 quarters · filed 2026-08-05 | $146.35M 10-Q · filed 2025-11-06 | $190.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $47.59M 10-Q · filed 2026-08-05 | $95.22M 10-Q · filed 2026-08-05 | $139.08M derived: sum of 3 quarters · filed 2026-08-05 | $185.20M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $47.63M 10-Q · filed 2026-05-05 | $91.49M derived: sum of 2 quarters · filed 2026-05-05 | $137.62M derived: sum of 3 quarters · filed 2026-05-05 | $180.58M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $43.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $89.99M derived: sum of 2 quarters · filed 2026-02-25 | $132.95M derived: sum of 3 quarters · filed 2026-02-25 | $181.59M 10-K · filed 2026-02-25 |
| 2024-09-30 | $46.13M 10-Q · filed 2025-11-06 | $89.09M derived: sum of 2 quarters · filed 2025-11-06 | $137.73M 10-Q · filed 2025-11-06 | $174.68M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $42.96M 10-Q · filed 2025-08-06 | $91.60M 10-Q · filed 2025-08-06 | $128.56M derived: sum of 3 quarters · filed 2026-02-25 | $166.88M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $48.64M 10-Q · filed 2025-05-06 | $85.59M derived: sum of 2 quarters · filed 2026-02-25 | $123.92M derived: sum of 3 quarters · filed 2026-02-25 | $166.28M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $36.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $75.28M derived: sum of 2 quarters · filed 2026-02-25 | $117.63M derived: sum of 3 quarters · filed 2026-02-25 | $153.65M 10-K · filed 2026-02-25 |
| 2023-09-30 | $38.33M 10-Q · filed 2024-11-07 | $80.68M derived: sum of 2 quarters · filed 2024-11-07 | $116.70M 10-Q · filed 2024-11-07 | $153.22M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $42.35M 10-Q · filed 2024-08-06 | $78.38M 10-Q · filed 2024-08-06 | $114.89M derived: sum of 3 quarters · filed 2025-02-21 | $147.19M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $36.02M 10-Q · filed 2024-05-07 | $72.54M derived: sum of 2 quarters · filed 2025-02-21 | $104.84M derived: sum of 3 quarters · filed 2025-02-21 | $147.14M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $36.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $68.82M derived: sum of 2 quarters · filed 2025-02-21 | $111.12M derived: sum of 3 quarters · filed 2025-02-21 | $157.95M 10-K · filed 2025-02-21 |
| 2022-09-30 | $32.30M 10-Q · filed 2023-11-02 | $74.61M derived: sum of 2 quarters · filed 2023-11-02 | $121.44M 10-Q · filed 2023-11-02 | $167.07M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $42.30M 10-Q · filed 2023-08-03 | $89.14M 10-Q · filed 2023-08-03 | $134.77M derived: sum of 3 quarters · filed 2024-02-27 | $178.98M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $46.83M 10-Q · filed 2023-05-04 | $92.47M derived: sum of 2 quarters · filed 2024-02-27 | $136.68M derived: sum of 3 quarters · filed 2024-02-27 | $169.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $45.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $89.84M derived: sum of 2 quarters · filed 2024-02-27 | $122.99M derived: sum of 3 quarters · filed 2024-02-27 | $153.20M 10-K · filed 2024-02-27 |
| 2021-09-30 | $44.21M 10-Q · filed 2022-11-08 | $77.36M derived: sum of 2 quarters · filed 2022-11-08 | $107.57M 10-Q · filed 2022-11-08 | $132.05M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $33.15M 10-Q · filed 2022-08-04 | $63.36M 10-Q · filed 2022-08-04 | $87.84M derived: sum of 3 quarters · filed 2023-03-15 | $108.72M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $30.21M 10-Q · filed 2022-05-05 | $54.69M derived: sum of 2 quarters · filed 2023-03-15 | $75.58M derived: sum of 3 quarters · filed 2023-03-15 | $100.01M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $24.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $45.37M derived: sum of 2 quarters · filed 2023-03-15 | $69.80M derived: sum of 3 quarters · filed 2023-03-15 | $93.14M 10-K · filed 2023-03-15 |
| 2020-09-30 | $20.89M 10-Q · filed 2021-11-03 | $45.32M derived: sum of 2 quarters · filed 2021-11-03 | $68.66M 10-Q · filed 2021-11-03 | $88.68M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $24.43M 10-Q · filed 2021-08-04 | $47.78M 10-Q · filed 2021-08-04 | $67.80M derived: sum of 3 quarters · filed 2022-02-28 | $89.10M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $23.34M 10-Q · filed 2021-05-04 | $43.36M derived: sum of 2 quarters · filed 2022-02-28 | $64.67M derived: sum of 3 quarters · filed 2022-02-28 | $87.89M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $20.02M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $41.33M derived: sum of 2 quarters · filed 2022-02-28 | $64.54M derived: sum of 3 quarters · filed 2022-02-28 | $80.75M 10-K · filed 2022-02-28 |
| 2019-09-30 | $21.31M 10-Q · filed 2020-11-04 | $44.53M derived: sum of 2 quarters · filed 2020-11-04 | $60.73M 10-Q · filed 2020-11-04 | $78.50M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $23.22M 10-Q · filed 2020-08-06 | $39.43M 10-Q · filed 2020-08-06 | $57.19M derived: sum of 3 quarters · filed 2021-03-10 | $72.70M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $16.21M 10-Q · filed 2020-05-07 | $33.97M derived: sum of 2 quarters · filed 2021-03-10 | $49.48M derived: sum of 3 quarters · filed 2021-03-10 | $70.39M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $17.77M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $33.27M derived: sum of 2 quarters · filed 2021-03-10 | $54.18M derived: sum of 3 quarters · filed 2021-03-10 | $73.19M 10-K · filed 2021-03-10 |
| 2018-09-30 | $15.51M 10-Q · filed 2019-11-06 | $36.42M derived: sum of 2 quarters · filed 2019-11-06 | $55.43M 10-Q · filed 2019-11-06 | $70.22M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $20.91M 10-Q · filed 2019-08-07 | $39.92M 10-Q · filed 2019-08-07 | $54.72M derived: sum of 3 quarters · filed 2020-03-10 | $68.48M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $19.01M 10-Q · filed 2019-05-08 | $33.80M derived: sum of 2 quarters · filed 2020-03-10 | $47.57M derived: sum of 3 quarters · filed 2020-03-10 | $62.70M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $28.56M derived: sum of 2 quarters · filed 2020-03-10 | $43.69M derived: sum of 3 quarters · filed 2020-03-10 | $57.96M 10-K · filed 2020-03-10 |
| 2017-09-30 | $13.76M 10-Q · filed 2018-11-06 | $28.89M derived: sum of 2 quarters · filed 2018-11-06 | $43.16M 10-Q · filed 2018-11-06 | $54.56M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $15.13M 10-Q · filed 2018-08-07 | $29.40M 10-Q · filed 2018-08-07 | $40.80M derived: sum of 3 quarters · filed 2019-03-12 | $47.94M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $14.27M 10-Q · filed 2018-05-09 | $25.67M derived: sum of 2 quarters · filed 2019-03-12 | $32.81M derived: sum of 3 quarters · filed 2019-03-12 | $39.90M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $11.40M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $18.54M derived: sum of 2 quarters · filed 2019-03-12 | $25.63M derived: sum of 3 quarters · filed 2019-03-12 | $32.67M 10-K · filed 2019-03-12 |
| 2016-09-30 | $7.14M 10-Q · filed 2017-11-07 | $14.23M derived: sum of 2 quarters · filed 2017-11-07 | $21.27M 10-Q · filed 2017-11-07 | $26.27M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $7.09M 10-Q · filed 2017-08-08 | $14.13M 10-Q · filed 2017-08-08 | $19.13M derived: sum of 3 quarters · filed 2018-03-07 | $23.15M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $7.04M 10-Q · filed 2017-05-10 | $12.04M derived: sum of 2 quarters · filed 2018-03-07 | $16.06M derived: sum of 3 quarters · filed 2018-03-07 | $19.14M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $9.02M derived: sum of 2 quarters · filed 2018-03-07 | $12.11M derived: sum of 3 quarters · filed 2018-03-07 | $14.79M 10-K · filed 2018-03-07 |
| 2015-09-30 | $4.02M 10-Q · filed 2016-11-14 | $7.10M derived: sum of 2 quarters · filed 2016-11-14 | $9.79M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $3.08M 10-Q · filed 2016-09-15 | $5.77M 10-Q · filed 2016-09-15 | ||
| 2014-12-31 | $9.32M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |